Firmonertinib Clinical Trials
3 recruitingDrug
Phase 32Phase 41
Showing 1–3 of 3 trials
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
ArriVent BioPharma, Inc.480 enrolled56 locationsNCT07185997
Recruiting
Phase 4
Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
NSCLCLeptomeningeal MetastasisTyrosine Kinase Inhibitor+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology40 enrolled1 locationNCT07092202
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
NSCLCAdjuvant Treatment
Allist Pharmaceuticals, Inc.338 enrolled2 locationsNCT07010419